VA Northern California Health Care System | Sacramento VA Medical Center
Status and phase
Conditions
Treatments
About
This is a Phase 3, multicenter, randomized, double-blind, safety and efficacy study of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) administered for a total of 14 to 28 days in adult subjects with moderate or severe DFI.
Full description
Approximately 865 subjects (519 contezolid acefosamil/contezolid: 346 linezolid) will be enrolled with moderate or severe DFI that are confirmed or suspected to be due to a Gram-positive bacterial pathogen (MITT analysis set).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
865 participants in 2 patient groups
Loading...
Central trial contact
Clinical coordinator
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal